EMA Reviews Allergan Fibroid Drug After Liver Injuries

Dec 04, 2017

The European Medicines Agency (EMA) has started a review of Allergan’s Esmya, a drug used to treat uterine fibroids, following reports of serious liver injuries.

The review comes after four reports of serious liver injury, three of which ended in liver transplants, in patients treated with the drug. The EMA's Pharmacovigilance Risk Assessment Committee will investigate whether there is a causal link between Esmya and liver damage.

Esmya, which is still awaiting approval from the U.S. FDA, was approved in the EU in 2012 for the treatment of moderate to severe symptoms of uterine fibroids.

Read the EMA statement 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments